Clinical Trials Logo

Filter by:
NCT ID: NCT05941624 Recruiting - Sepsis Clinical Trials

Comparison Between HA330 Hemoperfusion Filter Hemodialysis and Conventional High-Flux Hemodialysis Filter

Start date: June 16, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the effectiveness between conventional hemodialysis and hemodialysis using hemoperfusion adsorbents in renal dysfunction caused by sepsis

NCT ID: NCT05939817 Completed - Keloid Clinical Trials

The Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial

Start date: October 1, 2021
Phase: Phase 4
Study type: Interventional

The objective of this study is to observe the potency of umbilical cord-derived mesenchymal stem cells (UC-MSC) and umbilical cord-derived conditioned medium (UC-CM), or triamcinolone acetonide (TA) in keloid therapy, measured by the decrease in the type 1:3 collagen ratio and the increase of IL-10 levels carried out using CONSORT statement.

NCT ID: NCT05939245 Recruiting - Clinical trials for Acute Kidney Injury Due to Sepsis

Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-resuscitation With Furosemide Group and Control Group

Start date: July 24, 2023
Phase: N/A
Study type: Interventional

The impact of early de-resuscitation with furosemide on patients with sepsis-related acute kidney injury using pNGAL as the parameter of acute kidney injury.

NCT ID: NCT05935423 Not yet recruiting - Clinical trials for ST Elevation Myocardial Infarction

Umbilical Cord Mesenchymal Stem Cell Improve Cardiac Function on ST-elevation Myocardial Infarction (STEMI) Patients

Start date: July 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to learn about the effectiveness of Umbilical Cord Mesenchymal Stem Cell (UC MSC) therapy in patients with STEMI against infarct myocardial size reduction and prevent the incidence of heart failure in the future

NCT ID: NCT05934890 Enrolling by invitation - Clinical trials for Pneumococcal Disease, Invasive

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13

Start date: November 23, 2023
Phase: Phase 3
Study type: Interventional

Hypothesis of non-inferiority test for seropositive rate and GMC in each serotype

NCT ID: NCT05930600 Recruiting - Clinical trials for Fluid Responsiveness

Internal Jugular Venous Distensibility Index and Innominate Venous Flow Patterns as Predictors of Fluid Responsiveness

Start date: June 15, 2023
Phase:
Study type: Observational

The measurement of internal jugular vein distensibility index corresponds to the measurement of stroke volume using trans-thoracic Doppler echocardiography in assessing the response to fluid administration in elective surgical patients.

NCT ID: NCT05925829 Completed - Clinical trials for Diabetes Mellitus, Type 2

Stromal Vascular Fraction and Autologous Activated Platelet-Rich Plasma Combination in Treating Treatment of Type 2 Diabetes

Start date: January 1, 2017
Phase: Phase 1
Study type: Interventional

This study was a retrospective study on type 2 diabetes patients that were treated with autologous stromal vascular fraction (SVF) and autologous activated platelet-rich plasma (aaPRP) measuring HbA1c level at baseline, 1-month, 3-month, 6-month, and 12-month post-treatment.

NCT ID: NCT05925647 Completed - Clinical trials for Rheumatoid Arthritis

The Effects of Mesenchymal Stem Cell Secretome in Rheumatoid Arthritis Patients

Start date: August 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This research is a clinical trial of administering mesenchymal stem cell secretome to rheumatoid arthritis patients.

NCT ID: NCT05921058 Completed - Lupus Erythematosus Clinical Trials

The Effects of Mesenchymal Stem Cell Secretome in Lupus Patients

Start date: August 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This research is a clinical trial of administering mesenchymal stem cell secretome to lupus patients.

NCT ID: NCT05918939 Recruiting - COVID-19 Pandemic Clinical Trials

UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)

Start date: September 5, 2022
Phase: Early Phase 1
Study type: Interventional

This is an observer blind randomized controlled trial study to evaluate the humoral immunogenicity profile - neutralizing antibody - after 28 days following vaccination with Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) vaccine as heterologue booster compared with CoronaVac administered intramuscularly in healthy adults age 18 year and above. Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) vaccine is an inactivated vaccine made of SARS-CoV-2 virus isolated from a patient in Surabaya, composed with aluminium hydroxy gel, tween 80, and L-histidine, and this will be the first booster study in human.